PT Widatra Bhakti

What PT Widatra Bhakti does

PT Widatra Bhakti is an Indonesian pharmaceutical manufacturer, founded in 1986 and headquartered in South Jakarta, that produces basic and specialty intravenous (parenteral) solutions for the Indonesian healthcare market. The company operates a single manufacturing facility in Pandaan, East Java, and runs two product lines: generic IV fluids (Sodium Chloride 0.9%, Ringer Lactate) and a branded WIDA product family (WIDA NS, WIDA RL, WIDA D5-NS, WIDA D5-1/2NS, WIDA D5-1/4NS, WIDA 2A, WIDA RD, WIDA WI Unicap, WIDA KN-2), plus specialty balanced crystalloid and colloid solutions (WIDABES, WIDAHES BES) indicated for resuscitation and COVID-19-era fluid therapy. All products use double-port rubber cap packaging on plastic bottles (500 mL and 1000 mL formats) and carry BPOM (NIE) registrations, ISO 9001/14001/45001 certifications, and Halal certification.

The company is privately held and is a subsidiary of Otsuka Holdings Co., Ltd. (Japan), operating alongside other Otsuka Group entities in Indonesia (PT Otsuka Indonesia, PT Amerta Indah Otsuka, PT Otsuka Distribution Indonesia, PT Lautan Otsuka Chemical). Pricing is not publicly disclosed; products are procured through the government e-Catalogue (LKPP-Kemenkes) under the JKN-KIS national health insurance program, with PT Merapi Utama Pharma acting as the primary national distributor and field sales teams engaging hospitals, clinics, and puskesmas directly. The company self-identifies as the largest basic parenteral solution manufacturer in Indonesia and respected in the Asian region, serving government and private hospitals, community health centers, and pharmacy professionals through exhibitions (Hospital Expo, Rakerkesnas, Rakornas MPKU), medical association partnerships (HISFARSI, IAI, PERDATIN, PERDAMSI), and CSR programs.

The business model is fundamentally a B2B pharmaceutical manufacturer revenue stream: hardware-style product sales (commoditized IV fluids) distributed via a single exclusive distributor plus direct institutional sales and government e-Catalogue participation, with multi-year procurement contracts. Customer-facing engagement is conducted through healthcare professional education (webinars, in-house trainings, association events) rather than traditional consumer marketing. Headcount is not precisely disclosed but 1,300+ employees and family members attended the 2024 Family Gathering, indicating a workforce of several hundred to approximately one thousand across the head office and Pandaan factory. Revenue is not publicly reported.

Name

PT Widatra Bhakti

Legal name

PT Widatra Bhakti

Website

https://widatra.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

51–100 employees

Short description

PT Widatra Bhakti is Indonesia's largest manufacturer of basic intravenous (parenteral) solutions, producing generic and branded IV fluids for hospitals, clinics, and government healthcare facilities under the JKN-KIS national health insurance program, and operating as a subsidiary of Japan's Otsuka Group.

Ownership category

akta.pro rank

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Manufacturing and Distribution: PT Widatra Bhakti manufactures and distributes basic and specialty intravenous (parenteral) solutions to healthcare institutions across Indonesia. Revenue is generated through the sale of generic and branded pharmaceutical products to hospitals, clinics, pharmacies, and government healthcare facilities via direct sales, distributor networks, and the national e-Catalogue procurement system.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

PT Widatra Bhakti manufactures and distributes basic and specialty intravenous (parenteral) solutions, offering both generic (Sodium Chloride 0.9%, Ringer Lactate) and WIDA branded products (WIDA NS, RL, D5-NS, D5-1/2NS, D5-1/4NS, 2A, RD, WI Unicap, KN-2). The company also produces balanced crystalloid/colloid solutions (WIDABES, WIDAHES BES) for fluid resuscitation. All products use double-port rubber cap packaging for sterile delivery.

Product overview

PT Widatra Bhakti is a pharmaceutical manufacturer specializing in parenteral solutions (IV fluids). The product portfolio consists of two main categories: basic intravenous solutions and specialty solutions, each available in both generic and branded product lines. All products use double port rubber caps. Generic products include Sodium Chloride 0.9% and Ringer Lactate. Branded products include WIDA NS (sodium chloride), WIDA RL (Ringer's lactate), WIDA D5-NS, WIDA D5-1/2NS, WIDA D5-1/4NS (dextrose-saline combinations), WIDA 2A (double electrolyte), WIDA RD (resuscitation fluid), WIDA WI Unicap (irrigation solution), and WIDA KN-2 (electrolyte solution). The company also produces balanced crystalloid and colloid products such as WIDABES and WIDAHES BES for fluid resuscitation.

Differentiator

Problem solved

Functional benefit

Brands

• WIDA: Product brand prefix for company's branded intravenous solution products including WIDA NS, WIDA RL, WIDA D5-NS, WIDA D5-1/2NS, WIDA D5-1/4NS, WIDA 2A, WIDA RD, WIDA WI Unicap, WIDA KN-2.

Products and services

• Sodium Chloride 0.9% Generic isotonic sodium chloride IV solution (308 mOsm/L) for plasma volume replacement when alkalosis hypochloremia exists, for hospitals and healthcare institutions.
• Ringer Lactate Generic Ringer's lactate IV solution (274 mOsm/L) for fluid replacement therapy in acid-base balance conditions, mild acidosis, emergency situations, and pre/intra/post-operative maintenance, for healthcare institutions.
• WIDA NS Branded sodium chloride 0.9% IV solution (308 mOsm/L) for replacing isotonic plasma loss when alkalosis hypochloremia exists, using double port rubber cap packaging, for hospitals and healthcare institutions.
• WIDA RL Branded Ringer's lactate IV solution (274 mOsm/L) for fluid replacement therapy in acid-base balance conditions, mild acidosis, emergency situations, and pre/intra/post-operative maintenance, using double port rubber cap packaging, for healthcare institutions.
• WIDA D5 - NS Branded dextrose 5% in normal saline IV solution (560 mOsm/L, 190 kcal/L) for dehydration treatment, calorie supplementation, and electrolyte balance restoration, for hospitals and healthcare institutions.
• WIDA D5 - 1/2 NS Branded dextrose 5% in half-strength normal saline IV solution (406 mOsm/L, 190 kcal/L) for dehydration treatment, calorie supplementation, and electrolyte balance restoration, for healthcare institutions.
• WIDA D5 - 1/4 NS Branded dextrose 5% in quarter-strength normal saline IV solution (329 mOsm/L, 190 kcal/L) for dehydration treatment, calorie supplementation, and electrolyte balance restoration, for healthcare institutions.
• WIDA 2A Branded double electrolyte IV solution (280 mOsm/L, 95 kcal/L) providing sodium and chloride for dehydration treatment, calorie supplementation, and electrolyte balance restoration, for healthcare institutions.
• WIDA RD Branded resuscitation/dextrose IV solution (564 mOsm/L) for energy improvement, isotonic dehydration treatment, fluid replacement therapy, and acid-base balance restoration in mild acidosis, for healthcare institutions.
• WIDA WI Unicap Branded irrigation solution for surgical use, wound cleaning, pad moisturizing, and medical device soaking and cleaning, for surgical and clinical settings.
• WIDA KN-2 Branded electrolyte IV solution (388 mOsm/L) providing water and electrolyte supplementation for patients, for hospitals and healthcare institutions.
• WIDABES Specialty balanced crystalloid IV solution with electrolyte composition closer to plasma, recommended for fluid resuscitation and COVID-19 patient therapy, for hospitals and intensive care units.
• WIDAHES BES Specialty balanced colloidal IV solution for resuscitation and balanced colloidal therapy, for hospitals and intensive care units.

Quantifiable outcome

• Leading and largest basic IV solution manufacturer in Indonesia and respected in the Asian Region
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Tzu Chi Hospital (Yayasan Buddha Tzu Chi)minorOthers · 22 September 2022PT Widatra Bhakti, through its distributor PT Merapi Utama Pharma, donated 2,000 bottles of IV fluids to Tzu Chi Hospital on September 22, 2022, for distribution to flood victims in Pakistan.
• Kementerian Kesehatan Republik Indonesia (Ministry of Health RI)coreOthers · 18 February 2020PT Widatra Bhakti participates in Rakerkesnas 2020 organized by the Ministry of Health, showcasing products alongside PT Otsuka Indonesia's basic fluid products to healthcare practitioners and government health officials from across Indonesia.
• HNGV (Hospital Nacional Guido Valaderes) Timor LesteminorStrategic or Co-development Partner · 5 April 2018PT Widatra Bhakti collaborated with HNGV Timor Leste to conduct an In House Training on April 5, 2018, on 'Update On Fluid Therapy' for 78 healthcare workers including specialists, general practitioners, nurses, and pharmacy staff.
• PT Merapi Utama PharmacoreChannel Partner/ Reseller/ DistributorPT Merapi Utama Pharma serves as the primary distributor of PT Widatra Bhakti's infusion products, handling national distribution to hospitals and healthcare facilities across Indonesia. They collaborate at exhibitions such as Hospital Expo 2019 and facilitate product delivery to healthcare institutions.
• Otsuka Group Indonesia Companies (PT Otsuka Indonesia, PT Amerta Indah Otsuka, PT Otsuka Distribution Indonesia, PT Lautan Otsuka Chemical)coreStrategic or Co-development PartnerPT Widatra Bhakti is a member of the Otsuka Group in Indonesia. The company shares headquarters with other Otsuka Group companies at Pondok Indah Office Tower. They co-participate in Christmas celebrations, CSR activities, and the group is supported by parent company Otsuka Holdings Co., Ltd. which was named to CDP Climate A List for two consecutive years.
• PERDATIN (Perhimpunan Dokter Anestesi dan Terapi Intensif Seluruh Indonesia)minorStrategic or Co-development PartnerPERDATIN collaborated with PT Widatra Bhakti to conduct a COVID-19 fluid therapy webinar on August 21, 2020, attended by approximately 300 participants. Widatra presented its balanced crystalloid product WIDABES for COVID-19 patients.
• PERDAMSI (Perhimpunan Dokter Ahli Emergensi Indonesia)minorStrategic or Co-development PartnerPERDAMSI supported the second COVID-19 fluid therapy webinar on August 22, 2020, with approximately 250 participants consisting mainly of emergency room doctors.
• HISFARSI (Himpunan Seminat Farmasi Rumah Sakit Seluruh Indonesia)minorStrategic or Co-development PartnerPT Widatra Bhakti supports HISFARSI events including PIT and Munas ke-4 in Bali (July 2019), Rakerda Jawa Timur 2019, and Workshop Sulawesi Selatan 2019, promoting products to hospital pharmacists across Indonesia with the slogan 'Ayo Klik Widatra'.
• IAI (Ikatan Apoteker Indonesia)minorStrategic or Co-development PartnerPT Widatra Bhakti supported the Rakernas dan Pertemuan Ilmiah Tahunan IAI 2019 in Bandung, participating with an exhibition stand to inform approximately 2,000 pharmacists about its products.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Terumo Corporation: Japanese medical technology company producing IV solutions, infusion sets, and pharmaceutical containers. Comparable product mix and Otsuka's Japanese heritage makes Terumo a relevant regional competitor in sterile IV and blood-component solutions.
• Nipro Corporation: Japanese medical device and pharmaceutical manufacturer producing IV solutions, dialysis products, and injection devices. Operates in Southeast Asia and competes with Widatra in sterile IV fluids and hospital injectables.
• PT Otsuka Indonesia: Indonesian Otsuka Group sister company producing IV-related fluids and pharmaceutical products. While both are Otsuka-owned, they co-exhibit and operate in overlapping hospital channels, making Otsuka Indonesia the closest product-line peer within the same group.
• ICU Medical: U.S.-based medical device and IV therapy company producing IV fluids, infusion sets, and connection systems. A direct competitor in sterile IV fluids and infusion therapy for hospital customers globally.

Regional players

• PT Kalbe Farma: Indonesia's largest pharmaceutical company, producing a broad range of prescription and consumer health products including IV-related therapies. Operates in the same Indonesian hospital channel and JKN-KIS procurement system as Widatra, though with a much broader therapeutic portfolio.
• PT Hexpharm Jaya: Indonesian pharmaceutical manufacturer with a strong presence in generic injectables and IV products. A domestic competitor in the Indonesian hospital generic IV segment, competing for e-Catalogue and hospital procurement contracts.

Broad incumbents

• B. Braun Melsungen: Global German medical and IV solutions manufacturer with established Indonesian operations through PT B. Braun Indonesia. Directly competes in sterile IV fluids, infusion therapy, and hospital nutrition with a much broader global portfolio than Widatra.
• Baxter International: U.S.-based global leader in IV solutions, injectable drugs, and sterile fluids. Operates across Southeast Asia and competes directly with Widatra in the hospital IV fluids category, with significantly broader geographic and product reach.
• Fresenius Kabi: Global German healthcare company specializing in IV generics, infusion solutions, and clinical nutrition. A direct international competitor to Widatra in the basic and balanced crystalloid IV fluids space across Asia.

Others

• Otsuka Pharmaceutical (Otsuka Holdings): The Japanese parent company of PT Widatra Bhakti. While not a direct competitor, Otsuka Holdings shapes Widatra's strategic direction, capital allocation, and access to group technology and distribution infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT Widatra Bhakti